Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

6 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-09-01

Study Completion Date

2017-03-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will compare the use of two contrast agents to analyze blood flow characteristics of brain tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis

NCT00285324

Glioma Tumor Recurrence Radiation Necrosis Primary Brain Tumor

COMPLETED

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

NCT00659126

Metastatic Malignant Neoplasm in the Brain Primary Brain Neoplasm

TERMINATED PHASE2

Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery

NCT02590497

Glioblastoma

WITHDRAWN NA

Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors

NCT00005790

Brain and Central Nervous System Tumors

WITHDRAWN NA

Study of Stored Tumor Samples in Young Patients With Brain Tumors

NCT00897286

Brain and Central Nervous System Tumors

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will compare contrast agents, gadobenate dimeglumine and gadobutrol, for MRI perfusion analysis in brain tumor patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Nervous System Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with brain tumors will be enrolled. These subjects may be newly diagnosed, undergoing treatment or undergoing follow-up. If a subject has undergone surgery or treatment they should have what appears to be residual tumor.

Exclusion Criteria

* Renal failure (GFR \<45). Subjects will be screened utilizing UNMC gadolinium contrast guidelines.
* Allergic reactions to MRI contrast agents.
* Subjects who do not fit the criteria for the population we are evaluating.
* Subjects should not participate in this study if they have any of the following conditions:

* Anxiety attacks
* Panic disorder
* Claustrophobia
* Pregnant, or trying to become pregnant
* Breast feeding
* Subjects should not participate in this study if they have certain kinds of metal in their body, for example: a heart pacemaker, defibrillator, neurostimulator, a metal plate, certain otologic implants, certain types of heart valves, metal slivers in eye, brain aneurysm clips or metal slivers and bullet fragments in or near certain structures in their body. Our standard MRI safety screening will be performed on all subjects.
* If a subject has metal in their body that requires an additional x-ray beyond what is needed for the clinical MRI examination to safely perform the research MRI examination that subject would be excluded.Subjects not being able to return for a follow-up examination

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No